Global Cancer Diagnostics Market 2018-2024
- December, 2017
- Domain: Healthcare - Diagnostics
- Get Free 10% Customization in this Report
Overview: Cancer diagnostic testing involves tests and procedures that confirms the presence of disease and identify the correct tumor type, location, extent and stage which will help physician to give the appropriate treatment. Biopsy, imaging tests, nuclear medicine scans, tumor biomarker tests are some of the diagnostic tests used for cancer diagnostics. According to the estimation of National cancer institute, in US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. Canada has estimated 202,400 new cases of cancer and nearly 78,000 deaths according to Canadian cancer society in 2016. While in Europe, 1.3 million people were diagnosed in 2015. According to National cancer institute, nearly 60% new cases of cancer are from Asia, Africa, Central and South American countries and nearly 70% of cancer deaths are also from this region. China has witnessed 4.3 million new cases of cancer and 2.8 million deaths in 2015. According to Indian council for medical research, India accounts for 1.4 million new cases of cancer and 736,000 cancer related death in 2016.
The cancer diagnostics market is booming due to increasing incidence of cancer globally, growing elderly population across the globe, increased use of personalized medicine in clinical practice, and development of new novel technologies such as nanotechnology. However, lack of skilled labors and high cost of diagnosis are some of the factors hampering the market growth to an extent.
Market Analysis: The “Global Cancer Diagnostics Market” is estimated to witness a CAGR of 11.6% during the forecast period 2018–2024. The market is analyzed based on four segments – method of diagnosis, application, end-user and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The North America is set to be the leading region for the cancer diagnostics market growth followed by Europe, Asia Pacific and Rest of the World.
Method of diagnosis Analysis: The global Cancer Diagnostics market by method of diagnosis is segmented into tumor biomarker tests, tissue diagnostics (biopsy), liquid biopsy, imaging, and others. Imaging occupied the largest share in 2017, and liquid biopsy is expected to grow at a high CAGR in the coming years due to high preference of molecular based non-invasive tests, and increasing adoption of personalized medicine. Imaging is further segmented into magnetic resonance imaging, computed tomography, ultrasound, mammography, and nuclear imaging.
Application Analysis: The global cancer diagnostics market by application is segmented into lung cancer, breast cancer, Colorectal cancer, prostate cancer and others. Lung cancer occupied the largest share in 2017, and breast cancer application is expected to be fastest growing segment during the forecasted period.
End-Users Analysis: The global cancer diagnostics market by end-users is segmented into Hospitals, diagnostic laboratories, academic & research institutes and others. Hospitals occupies a major share of cancer diagnostics market in 2017 and is expected to be same for next five years.
Key Players: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Inc., Siemens Healthineers (Siemens AG), Thermo Fisher Scientific, Inc., GE Healthcare, Qiagen N.V., Agilent Technologies, Inc., Hologic, Inc., Koninklijke Philips N. V. and other predominate & niche players.
Competitive Analysis: Currently, the imaging dominates the global cancer diagnostics market. The existing leading players and other predominant market players are concentrating on this market to offer advanced products. The key market players are acquiring other companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, key players are also launching new products to have edge in this market. For instance, in July 2017, the MEDITE Cancer Diagnostics, Inc., announced the launch of SureCyte C1 fluorogenic instant staining product universally. In April 2017, Roche announced the launch of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody, for the diagnosis of prostate cancer.
Benefits: The report provides complete details about the usage and adoption rate of cancer diagnostics products in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Advantage of cancer diagnostics
3.3 Disadvantage of cancer diagnostics
3.4 Segmented Addressable Market (SAM)
3.5 Trends of the cancer diagnostics market
3.6 Related Markets
3.6.1 Companion diagnostics
3.6.2 Genetic testing
3.6.3 Point-of-Care Diagnostics
4 Market Outlook
4.2 Funding scenario
4.3 Market segmentation
4.4 PEST Analysis
4.5 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Global Cancer Diagnostics Market Dynamics
126.96.36.199 Rising incidence of cancer globally
188.8.131.52Growing geriatric population
184.108.40.206 Growing demand of personalized medicine
220.127.116.11 Revolutionary nanotechnology in cancer diagnostics
18.104.22.168 Increasing medical tourism
22.214.171.124 High cost of diagnosis
126.96.36.199 Lack of skilled professionals
6 Method of Diagnosis: Market Size and Analysis
6.2 Tumor biomarker tests
6.3 Tissue diagnostics
6.4 Liquid biopsy
6.5.1 Magnetic resonance imaging (MRI)
6.5.2 Computed tomography (CT)
6.5.5 Nuclear imaging
7 Application: Market Size and Analysis
7.2 Lung cancer
7.3 Breast cancer
7.4 Colorectal cancer
7.5 Prostate cancer
8 End Users: Market Size and Analysis
8.3 Diagnostic Laboratories
8.4 Academic & research institutes
9 Regions: Market Size and Analysis
9.2 North America
9.5 Rest of the World
10 Competitive Landscape
11 Vendor Profiles
11.1 F.Hoffmann-La Roche Ltd
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.5 Business Focus
11.1.6 SWOT Analysis
11.1.7 Business Strategy
11.2 Abbott Laboratories
11.2.2 Business Unit
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategy
11.3 Siemens Healthineers (Siemens AG)
11.3.2 Business Units
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Thermo Fisher Scientific Inc.
11.4.2 Geographic Presence
11.4.3 Business Focus
11.4.4 SWOT Analysis
11.4.5 Business Strategies
11.5 GE Healthcare
188.8.131.52 Business unit
184.108.40.206 SWOT analysis
11.5.2 Business Strategy
12 Companies to Watch For
12.1 Qiagen N.V.
12.2 BioMerieux S.A.
12.2.2 BioMerieux S.A.: Recent Developments
12.3 Agilent Technologies, Inc
12.3.2 Agilent Technologies: Recent Developments
12.4 Becton Dickinson and Company
12.4.2 Becton dickenson and company: Recent Developments
12.5 Hologic Inc.
12.5.2 Hologic Inc.: Recent Developments
12.6 Illumina, Inc.
12.6.2 Illumina Inc.: Recent Developments
12.7 Koninklijke Philips N.V.
12.7.2 Koninklijke Philips N.V.: Recent Developments
TABLE 1 FUNDING SCENARIO 17
TABLE 2 GLOBAL CANCER DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 44
TABLE 3 OTHER PROMINENT VENDORS OF CANCER DIAGNOSTICS MARKET 54
TABLE 4 F. HOFFMANN-LA ROCHE: OFFERINGS 56
TABLE 5 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 57
TABLE 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS 63
TABLE 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 66
TABLE 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 72
TABLE 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 74
TABLE 10 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERINGS 81
TABLE 11 THERMO FISHER SCIENTIFIC INC.: RECENT DEVELOPMENTS 82
TABLE 12 GE HEALTHCARE: PRODUCT OFFERINGS 89
TABLE 13 GE HEALTHCARE: RECENT DEVELOPMENTS 90
TABLE 14 QIAGEN N.V.: SNAPSHOT 97
TABLE 15 QIAGEN N.V.: RECENT DEVELOPMENTS 97
TABLE 16 BIOMERIEUX S.A.: SNAPSHOT 100
TABLE 17 AGILENT TECHNOLOGIES: SNAPSHOT 102
TABLE 18 BECTON DICKINSON AND COMPANY: SNAPSHOT 105
TABLE 19 HOLOGIC INC.: SNAPSHOT 106
TABLE 20 ILLUMINA INC: SNAPSHOT 109
TABLE 21 KONINKLIJKE PHILIPS N.V.: SNAPSHOT 113
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.